Franklin Resources’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.1B Buy
2,722,071
+162,067
+6% +$124M 0.52% 42
2025
Q4
$1.98B Buy
2,560,004
+106,861
+4% +$72.6M 0.48% 39
2025
Q3
$1.38B Buy
2,453,143
+139,647
+6% +$79M 0.34% 64
2025
Q2
$1.21B Buy
2,313,496
+36,821
+2% +$20.6M 0.32% 74
2025
Q1
$1.44B Buy
2,276,675
+231,465
+11% +$159M 0.42% 52
2024
Q4
$1.46B Buy
2,045,210
+149,124
+8% +$125M 0.4% 52
2024
Q3
$1.91B Sell
1,896,086
-27,016
-1% -$30.1M 0.54% 36
2024
Q2
$2.02B Buy
1,923,102
+228,804
+14% +$222M 0.62% 27
2024
Q1
$1.63B Buy
1,694,298
+1,210,185
+250% +$1.15B 0.52% 38
2023
Q4
$425M Buy
484,113
+903
+0.2% +$744K 0.2% 134
2023
Q3
$398M Sell
483,210
-5,454
-1% -$4.29M 0.2% 122
2023
Q2
$351M Sell
488,664
-1,120
-0.2% -$864K 0.17% 153
2023
Q1
$402M Sell
489,784
-13,689
-3% -$10.3M 0.2% 128
2022
Q4
$363M Sell
503,473
-22,724
-4% -$16.8M 0.19% 142
2022
Q3
$362M Buy
526,197
+1,511
+0.3% +$951K 0.2% 135
2022
Q2
$310M Sell
524,686
-39,074
-7% -$25.4M 0.15% 168
2022
Q1
$394M Sell
563,760
-68,688
-11% -$43.5M 0.16% 163
2021
Q4
$399M Buy
632,448
+26,801
+4% +$16.5M 0.14% 181
2021
Q3
$367M Sell
605,647
-7,138
-1% -$4.43M 0.14% 192
2021
Q2
$342M Buy
612,785
+22,781
+4% +$11.5M 0.13% 199
2021
Q1
$279M Sell
590,004
-26,184
-4% -$12.7M 0.11% 218
2020
Q4
$298M Sell
616,188
-104,349
-14% -$56.3M 0.13% 198
2020
Q3
$403M Buy
720,537
+26,793
+4% +$16.2M 0.2% 136
2020
Q2
$442M Buy
693,744
+110,879
+19% +$62.9M 0.23% 117
2020
Q1
$285M Sell
582,865
-76,316
-12% -$31.5M 0.19% 144
2019
Q4
$248M Sell
659,181
-42,834
-6% -$14.4M 0.13% 197
2019
Q3
$195M Buy
702,015
+20,208
+3% +$5.98M 0.11% 234
2019
Q2
$213M Buy
681,807
+112,147
+20% +$37.3M 0.11% 218
2019
Q1
$234M Sell
569,660
-10,047
-2% -$4.14M 0.13% 212
2018
Q4
$217M Sell
579,707
-73,178
-11% -$26.8M 0.13% 203
2018
Q3
$264M Sell
652,885
-37,070
-5% -$14.1M 0.13% 203
2018
Q2
$238M Sell
689,955
-77,905
-10% -$24.4M 0.12% 206
2018
Q1
$264M Sell
767,860
-51,936
-6% -$18.1M 0.13% 195
2017
Q4
$308M Buy
819,796
+35,123
+4% +$14.2M 0.15% 183
2017
Q3
$351M Buy
784,673
+8,415
+1% +$4M 0.17% 159
2017
Q2
$381M Sell
776,258
-36,696
-5% -$16.1M 0.19% 143
2017
Q1
$315M Sell
812,954
-98,673
-11% -$36.6M 0.16% 169
2016
Q4
$335M Buy
911,627
+127,891
+16% +$48.6M 0.17% 149
2016
Q3
$315M Buy
783,736
+20,901
+3% +$8.38M 0.16% 164
2016
Q2
$266M Buy
762,835
+95,552
+14% +$36.8M 0.14% 179
2016
Q1
$241M Buy
667,283
+30,562
+5% +$12.6M 0.13% 200
2015
Q4
$346M Buy
636,721
+37,168
+6% +$20.1M 0.18% 148
2015
Q3
$279M Sell
599,553
-7,515
-1% -$4.04M 0.14% 171
2015
Q2
$310M Buy
607,068
+17,886
+3% +$8.73M 0.14% 171
2015
Q1
$266M Sell
589,182
-14,268
-2% -$6.05M 0.12% 194
2014
Q4
$248M Buy
603,450
+58,632
+11% +$23.1M 0.11% 201
2014
Q3
$196M Sell
544,818
-304,919
-36% -$102M 0.09% 230
2014
Q2
$240M Sell
849,737
-266,374
-24% -$78.9M 0.11% 214
2014
Q1
$335M Buy
1,116,111
+601,619
+117% +$185M 0.16% 154
2013
Q4
$142M Buy
514,492
+149,155
+41% +$42.9M 0.07% 290
2013
Q3
$114M Buy
365,337
+192,763
+112% +$50.7M 0.06% 316
2013
Q2
$38.8M Buy
+172,574
New +$40.2M 0.02% 585

Other funds holding REGN

Franklin Resources's REGN Position: Q1 2026 in Review

Franklin Resources increased its Regeneron Pharmaceuticals (REGN) stake by 6.3% in Q1 2026, buying an estimated $124M and bringing the position to 2,722,071 shares worth $2.1B. The position accounts for 0.52% of the portfolio, ranked #42.

Franklin Resources first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Franklin Resources held 2,722,071 shares of Regeneron Pharmaceuticals worth $2.1B as of Q1 2026.
  • Franklin Resources bought 162,067 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $124M.
  • Regeneron Pharmaceuticals made up 0.52% of Franklin Resources's portfolio in Q1 2026, its #42 holding.
  • Franklin Resources first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.